Capital Structure Week: AGH’s Audited Baseline, ANVS’s Financing Packet, XNDU’s Long‑Horizon Risk Map

This week’s Market Tide Weekly maps capital structure across AGH’s 10‑K, ANVS’s financing packet, and XNDU’s long‑horizon 20‑F risk stack.

Market Tide Weekly — (Tuesday Edition)

Structural Summary
The tape was loud. The filings were quieter. They were also more useful. The week’s common thread was capital structure: who gets shares, when they unlock, and what the business can fund before the next raise.

We anchored the read in three documents—three layers of market plumbing. AGH’s 10-K is the audited baseline: operating reality, liquidity, and obligations. ANVS’s 424B5 + 8-K is the financing packet: shares issued, warrants layered, timing set, proceeds stated. XNDU’s 20-F is the long-horizon risk stack: losses, burn, and continued capital dependence.

Rule stays the same: price reacts. Filings define structure. We’re mapping what the company disclosed about funding, obligations, and potential dilution.

Summary:
• Theme: supply mechanics. Runway, obligations, and issuance pathways set the range of outcomes.
• AGH (10-K): audited baseline—operations, liquidity, and obligations.
• ANVS (424B5 + 8-K): financing packet—share issuance now, warrant supply later.
• XNDU (20-F): long-horizon risk stack—cash burn and continued capital dependence.
• Next-week focus: registrations, follow-on 8-Ks, warrant/convertible actions, and compliance triggers.

How We Picked These (Method)

·        Screen for velocity. Then move to primary documents.

·        Choose filings that define mechanics: operations, liquidity, obligations, and supply.

·        Translate into a map: what exists, what unlocks, what forces the next raise.

·        No targets. No hype. No claims without disclosure.

This Week’s Structural Theme: Supply mechanics. Runway, obligations, and issuance pathways set the range of outcomes.

Public Pick #1 — AGH — Aureus Greenway Holdings Inc

·       Why it surfaced: This is the cleanest “audited baseline” on the screen this week—an annual report that forces the tape back onto operating reality.

·       What the filing gives you: A complete, audited snapshot for the fiscal year ended December 31, 2025—including operating performance, liquidity framing, and the disclosure posture the company uses to describe its risks and constraints. On the cover page: the company lists its common stock trading on The Nasdaq Stock Market LLC under AGH and identifies Commission File Number 001-42507.

·       How to read it (filings-first lens): Start with the “survival math” first, then narrative: (1) liquidity and cash runway, (2) obligations that create fixed outflows, (3) whether the disclosure indicates reliance on additional financing, and (4) the security stack that can translate price strength into new share supply.

·       Key numbers to pull: cash; operating cash flow/burn; total debt; shares outstanding + convertibles; any going-concern / financing-dependence language tied to the numbers.

·       What to watch next: Follow-on 8-Ks and any registration activity that changes either (a) capital availability or (b) the effective float—because those levers can move faster than operations.

Public Pick #2 — ANVS — Annovis Bio Inc

·       Why it surfaced: A financing packet where the dilution mechanics are explicitly spelled out—pricing, warrant terms, and stated use of proceeds.

·       What changed structurally: The company disclosed an underwritten registered direct offering of 5,263,156 shares with accompanying warrants to purchase up to 5,263,156 shares (one warrant per share), at a combined price of $1.90 per share + warrant. The warrants are exercisable six months after issuance, have a $2.50 exercise price, and expire five years and six months after issuance.

·        Key numbers to pull: shares sold; warrant count; strike; exercisable date; expiry; gross proceeds vs. underwriting/fees.

ANVS 424B5 — Offering Terms (Quick Block)

·        Securities offered: 5,263,156 shares of common stock + warrants to purchase up to 5,263,156 shares (one warrant per share).

·        Structure: shares and warrants are immediately separable and issued separately, but can only be purchased together in the offering.

·        Price: combined public offering price of $1.90 per share + accompanying warrant.

·        Warrant terms: exercisable six months after issuance; exercise price $2.50 per share; expires five and one-half years from issuance.

·        Market notes: common stock trades under ANVS; the warrants have no established trading market and there is no stated plan to list them.

·        424B5 table snapshot: gross proceeds (offering price) approx. $9,999,996.40; underwriting discounts/commissions approx. $649,999.77; proceeds to company before expenses/fees approx. $9,349,996.63.

·       How to read it (filings-first lens): Treat it as a two-layer supply map: (1) immediate common stock issued now, and (2) the “second wave” represented by warrants once exercisable. Then compare stated use of proceeds (clinical program + working capital) against the likely time-to-next-catalyst.

·       What to watch next: Any subsequent filings clarifying closing, use-of-proceeds updates, or additional capital actions—because late-stage biotech timelines often pull funding events forward.

Public Pick #3 — XNDU — Xanadu Quantum Technologies Ltd

·        Why it surfaced: A newly public, long-horizon R&D story where the filing makes the risk stack explicit: heavy losses, material cash burn, and dependence on future capital.

·        What the filing gives you: The annual Form 20-F reads like a long-horizon risk map: development-stage positioning, sustained losses, ongoing cash usage, and explicit dependence on future capital. It also lays out the operating model, key risks, and the timeline assumptions the company is asking the market to underwrite.

·        How to read it (filings-first lens): Focus on runway math and funding dependence: (1) cash and cash equivalents, (2) burn rate and accumulated deficit, (3) customer concentration and government-program reliance, and (4) any planned capital markets activity that could expand share supply.

·        Key numbers to pull: cash & equivalents; net loss; operating cash burn; accumulated deficit; any material debt/lease obligations; stated expectation of future financing (and timing cues).

·        What to watch next: Any registration statements (e.g., F-1) or additional foreign issuer reports (6-K) that indicate fundraising, share registration, or post-combination structural changes.

Glossary (quick terms)

·        10-K: U.S. annual report. Audited baseline (operations, liquidity, obligations).

·        20-F: annual report for foreign private issuers. Often the full risk + structure map.

·        424B5: sets the specific terms of an offering under an existing registration statement.

·        8-K: current report for material events (financing, agreements, corporate actions).

·        Warrant: right to buy shares at a fixed price before expiration.

·        Registered direct: shares sold directly to investors under an effective registration statement.

·        Float vs. shares outstanding: outstanding = total issued; float = available to trade.

·        Runway: time until cash is depleted at the current burn.

What We’re Watching Into Next Week

·        Registrations: S-1/F-1/S-3, resales, ATMs. New supply routes.

·        8-K follow-ons: closing terms, amendments, investor rights, use-of-proceeds changes.

·        Warrant/convertible actions: inducements, repricings, exchanges, exercises.

·        Runway pressure: payables, rollovers, tighter financing language.

·        Compliance: notices that force corporate actions.

Filings first. Structure second. Price last.